Jim McDermott, formerly at Aventis Pharmaceuticals, brings broad experience to developer of innovative nasal drug delivery devices
Kurve Technology, a developer of innovative nasal drug delivery devices, today announced veteran pharmaceutical executive and consultant Jim McDermott has joined the company's scientific consulting team.
McDermott was most recently director of US new products commercialisation for Aventis Pharmaceuticals where he managed a portfolio of phase I-III products, an alliance joint commercialisation team and business development activities, and was one of ten executives selected to develop the company's global customer focus transformation plan.
With more than 20 years of experience in the pharmaceutical industry, he has also worked for Roche Laboratories.
McDermott holds an MBA from Rockhurst College, and a BS degree in finance from Stonehill College.
"Jim's experience in product rollouts and market development will be instrumental in further establishing Kurve in the nasal drug delivery market," said Marc Giroux, CEO.
Kurve's ViaNase is the only known device that has nasally delivered chemical formulations to the paranasal sinuses in clinical testing.
It is based on Kurve's proprietary controlled particle dispersion technology that enables patients to quickly and painlessly administer drugs via the nose.
Kurve recently announced it has closed an $800,000 round of angel funding that allows the company to continue developing strategic partnerships.
Industry analysts believe that the global drug delivery market will show sharp growth over the next three to five years, forecasting the nasal drug delivery market growth at 15% a year to $9 billion by 2008.
